These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 30580670)

  • 21. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach.
    Shukla S; Kouanda A; Silverton L; Talele TT; Ambudkar SV
    Mol Pharm; 2014 Jul; 11(7):2313-22. PubMed ID: 24865254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I.
    Rocha KML; Nascimento ÉCM; de Jesus RCC; Martins JBL
    Molecules; 2024 Sep; 29(17):. PubMed ID: 39275102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
    Bagadi S; Saikia T; Pany A; Das B
    Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
    Jin B; Wang C; Shen Y; Pan J
    Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia.
    Georgoulia PS; Todde G; Bjelic S; Friedman R
    Biochim Biophys Acta Gen Subj; 2019 Apr; 1863(4):732-741. PubMed ID: 30684523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study.
    Zhang H; He X; Ni D; Mou L; Chen X; Lu S
    J Biomol Struct Dyn; 2020 Jan; 38(1):89-100. PubMed ID: 30661457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.
    Banavath HN; Sharma OP; Kumar MS; Baskaran R
    Sci Rep; 2014 Nov; 4():6948. PubMed ID: 25382104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
    El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
    Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
    Gupta P; Zhang GN; Barbuti AM; Zhang X; Karadkhelkar N; Zhou J; Ding K; Pan J; Yoganathan S; Yang DH; Chen ZS
    Cancer Lett; 2020 Mar; 472():132-141. PubMed ID: 31837444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
    Okabe S; Tauchi T; Tanaka Y; Sakuta J; Ohyashiki K
    Oncotarget; 2016 Aug; 7(33):53116-53126. PubMed ID: 27437766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
    Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the Abl
    Al Shahrani M; Gahtani RM; Abohassan M; Alasmari S; Makkawi M
    Med Oncol; 2023 Oct; 40(11):316. PubMed ID: 37789230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.
    Tanneeru K; Guruprasad L
    PLoS One; 2013; 8(11):e78556. PubMed ID: 24236021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
    Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
    Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
    Weisberg E; Manley PW; Cowan-Jacob SW; Hochhaus A; Griffin JD
    Nat Rev Cancer; 2007 May; 7(5):345-56. PubMed ID: 17457302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.